3M on Track for Highest Close Since February 2023 — Data Talk
3M Company (MMM) is currently at $96.46, up $4.31 or 4.67%
--Would be highest close since Feb. 7, 2023, when it closed at $97.74
--On pace for largest percent increase since April 1, 2024, when it rose 6.02%
--Currently up three consecutive days; up 5.53% over this period
--Best three day stretch since the three days ending April 2, 2024, when it rose 6.17%
--Up 8.78% month-to-date
--Up 5.54% year-to-date
--Down 55.39% from its all-time closing high of $216.23 on Jan. 26, 2018
--Up 12.04% from 52 weeks ago (May 2, 2023), when it closed at $86.10
--Would be a new 52-week closing high
--Up 34.79% from its 52-week closing low of $71.57 on Oct. 23, 2023
--Traded as high as $97.84; highest intraday level since Feb. 7, 2023, when it hit $98.00
--Up 6.16% at today's intraday high; largest intraday percent increase since April 1, 2024, when it rose as much as 6.38%
--Best performer in the DJIA today
--Fifth best performer in the S&P 500 today
--Contributed 28.31 points to the DJIA so far today
All data as of 11:11:53 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 30, 2024 11:29 ET (15:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks